Aduro Biotech has received $22.4 million in clinical development milestone payments from Janssen Biotech, the company’s license partner for ADU-214, ADU-741 and other products using Aduro’s LADD technology platform for the treatment of specific cancers. Janssen is responsible for all clinical development for the product candidates within the license agreements.

“Our relationship with Janssen has been exceptionally productive, with ADU-214 for the treatment of lung cancer and ADU-741 for the treatment of prostate cancer advancing in clinical studies,” said Stephen Isaacs, chairman, president and chief executive officer, Aduro. “We believe these therapeutics may offer important alternatives for patients suffering from these aggressive cancers.”

In May 2014 and October 2014, Aduro entered into two separate agreements with Janssen, granting exclusive, worldwide licenses to ADU-741 and other product candidates engineered for the treatment of prostate cancer, and ADU-214 and other product candidates engineered for the treatment of lung cancer and certain other cancers, based on its novel LADD immunotherapy platform.